Skip to main content
. 2024 Jan 5;8:e2300441. doi: 10.1200/PO.23.00441

FIG 2.

FIG 2.

Basic characteristics of trials using TITE-CRM and rolling 6. DLT, dose-limiting toxicity; TITE-CRM, time-to-event continuous reassessment method.